REVIEW PAPER
Diagnostics of atypical pulmonary infections
1
Department of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, Lodz, Poland Head of the Department: Dorota Pastuszak-Lewandoska PhD, MSc
Submission date: 2022-08-31
Final revision date: 2022-11-23
Acceptance date: 2023-01-31
Publication date: 2023-03-31
Corresponding author
Agnieszka Kiryszewska-Jesionek
Agnieszka Kiryszewska-Jesionek MD, PhD Department of Microbiology and Laboratory Medical Immunology Medical University of Lodz Lodz, Poland
Agnieszka Kiryszewska-Jesionek MD, PhD Department of Microbiology and Laboratory Medical Immunology Medical University of Lodz Lodz, Poland
Medical Studies 2023;39(1):65-72
KEYWORDS
TOPICS
ABSTRACT
Atypical community-acquired pneumonia (CAP) is a lung infection caused by atypical bacteria. It is associated with non-specific symptoms, the course of the disease is unusual and it poses a serious threat to patients. Even though CAP is quite prevalent, most cases remain undiagnosed, and clinicians rely solely on empirical therapy. The aim of this article is to characterize the most frequently used methods in diagnostics of atypical CAPs and evaluate their efficacy. A literature review showed that most of these techniques are still under development and there is a need for standardized diagnostic algorithms for atypical infections. Molecular panels and serological assays have been especially emphasized as they allow for rapid identification of etiologic agents and antibiotic resistance.
REFERENCES (65)
1.
Gründel A, Jacobs E, Dumke R. Interactions of surface-displayed glycolytic enzymes of Mycoplasma pneumoniae with components of the human extracellular matrix. Int J Med Microbiol 2016; 306: 675-685.
2.
Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008; 32: 956-973.
3.
Hahn DL. Chlamydia pneumoniae and chronic asthma: updated systematic review and meta-analysis of population attributable risk. PLoS One 2021; 16: e0250034.
4.
Arnold FW, Summersgill JT, Ramirez JA. Role of atypical pathogens in the etiology of community-acquired pneumonia. Semin Respir Crit Care Med 2016; 37: 819-828.
5.
Hahn DL. Chlamydia pneumoniae as a respiratory pathogen. Front Biosci 2002; 7: e66.
6.
Lind K, Benzon MW, Jensen JS, Clyde WA Jr. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995. Eur J Epidemiol 1997; 13: 581-586.
7.
Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J, Menzella F, Blasi F, Aliberti S, Restrepo MI; the GLIMP Study Group. Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. BMC Infect Dis 2018; 18: 677.
8.
Murdoch D, Chambers ST, Priest P. Clinical manifestations and diagnosis of Legionella infection. UpToDate 2020.
9.
Chitasombat MN, Ratchatanawin N, Visessiri Y. Disseminated extrapulmonary Legionella pneumophila infection presenting with panniculitis: case report and literature review. BMC Infect Dis 2018; 18: 467.
10.
Marchello C, Dale AP, Thai TN, Han DS, Ebell MH. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med 2016; 14: 552-566.
11.
Kang J. Challenges from atypical pathogens in diagnosis and treatment of community-acquired pneumonia. Comm Acquir Infect 2015; 2: 29-31.
12.
Izumikawa K, Izumikawa K, Takazono T, Kosai K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyaza- ki T, Tsukamoto M, Yanagihara K, Hara K, Kohno S. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother 2014; 20: 181-185.
13.
Saraya T, Kurai D, Ishii H, Ito A, Sasaki Y, Niwa S, Kiyo- ta N, Tsukagoshi H, Kozawa K, Goto H, Takizawa H. Epidemiology of virus-induced asthma exacerbations: with special reference to the role of human rhinovirus. Front Microbiol 2014; 5: 226.
14.
Wijesooriya WRPLI, Sunil-Chandra NP, Perera J. Reliability of cold agglutinin test (CAT) for the detection of patients with Mycoplasma pneumoniae pneumonia. Sri Lankan J Infect Dise 2016; 6: 25-32.
15.
Simmons WL, Dybvig K. Catalase enhances growth and biofilm production of Mycoplasma pneumoniae. Curr Microbiol 2015; 71: 190-194.
16.
Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev 2017; 30: 747-809.
17.
Xue G, Zhao H, Yan C, Li S, Cui J, Feng Y, Xie X, Yuan J. Evaluation of the CARDS toxin and its fragment for the serodiagnosis of Mycoplasma pneumoniae infections. Eur J Clin Microbiol Infect Dis 2021; 40: 1705-1711.
18.
Arfaatabar M, Noori Goodarzi N, Afshar D, Memariani H, Azimi G, Masoorian E, Pourmand MR. Rapid detection of Mycoplasma pneumoniae by loop-mediated isothermal amplification (LAMP) in clinical respiratory specimens. Iran J Public Health 2019; 48: 917-924.
19.
Li W, Liu Y, Zhao Y, Tao R, Li Y, Shang S. Rapid diagnosis of Mycoplasma pneumoniae in children with pneumonia by an immuno-chromatographic antigen assay. Sci Rep 2015; 5: 15539.
20.
Yang SI, Han MS, Kim SJ, Lee SY, Choi EH. Evaluation of a Rapid Diagnostic Antigen Test Kit Ribotest Mycoplasma® for the Detection of Mycoplasma pneumoniae. Pediatr Infect 2019; 26: 81-88.
21.
Zhang Y, Cao L, Xu Z, Zhu P, Huang B, Li K, Xu Y, Zhang Z, Wu Y, Di B. Evaluation of a multiplex PCR assay for detection of respiratory viruses and Mycoplasma pneumoniae in oropharyngeal swab samples from outpatients. J Clin Lab Anal 2020; 34: e23032.
22.
Saraya T, Ohkuma K, Tsukahara Y, Watanabe T, Kurai D, Ishii H, Kimura H, Goto H, Takizawa H. Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae. Respir Investig 2018; 56: 320-325.
23.
Saraya T, Watanabe T, Tsukahara Y, Ohkuma K, Ishii H, Kimura H, Yan K, Goto H, Takizawa H. The correlation between chest X-ray scores and the clinical findings in children and adults with Mycoplasma pneumoniae pneumonia. Intern Med 2017; 56: 2845-2849.
24.
Huo X, Xue X, Yuan S, Zhang D, Gao QE, Gong T. Early differential diagnosis between COVID-19 and mycoplasma pneumonia with chest CT scan. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49: 468-473.
25.
Gayam V, Konala VM, Naramala S, Garlapati PR, Merghani MA, Regmi N, Balla M, Adapa S. Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA. J Med Virol 2020; 92: 2181-2187.
26.
Coskun ME, Temel MT. Comparison of CRP, full blood count parameters and transaminases across different age groups of children with Mycoplasma pneumonia. Eur J Ther 2020; 26: 303-306.
27.
Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, Saito A, Kondo E, Teranishi H, Ogita S, Tanaka T, Kawasaki K, Nakano T, Terada K, Ouchi K. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 2013; 57: 2252-2258.
28.
Wu HM, Wong KS, Huang YC, Lai SH, Tsao KC, Lin YJ, Lin TY. Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan. J Infect Chemother 2013; 19: 782-786.
29.
FDA Drug Safety Communication: FDA Advises Restricting Fluoroquinolone Antibiotic Use for Certain Uncomplicated Infections; Warns about Disabling Side Effects That Can Occur Together; U.S. Food & Drug Administration: Silver Spring. MD, USA; 2016.
30.
Oishi T, Ouchi K. Recent trends in the epidemiology, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae. J Clin Med 2022; 11: 1782.
31.
Eisenreich W, Heuner K. The life stage-specific pathometabolism of Legionella pneumophila. FEBS Lett 2016; 590: 3868-3886.
32.
Faradonbeh FA, Khedri F, Doosti A. Legionella pneumophila in bronchoalveolar lavage samples of patients suffering from severe respiratory infections: role of age, sex and history of smoking in the prevalence of bacterium. Srp Arh Celok Lek 2015; 143: 274-278.
33.
Miyashita N, Horita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kiyota H, Watanabe A. Diagnostic predictors of Legionella pneumonia in Japan. J Infect Chemother 2018; 24: 159-163.
34.
Poirier R, Rodrigue J, Villeneuve J, Lacasse Y. Early radiographic and tomographic manifestations of legionnaires’ disease. Can Assoc Radiol J 2017; 68: 328-333.
35.
Mercante JW, Winchell JM. Current and emerging Legionella diagnostics for laboratory and outbreak investigations. Clin Microbiol Rev 2015; 28: 95-133.
36.
Borella P, Bargellini A, Marchesi I, Rovesti S, Stanca- nelli G, Scaltriti S, Moro M, Montagna MT, Tatò D, Napoli C, Triassi M, Montegrosso S, Pennino F, Zotti CM, Ditommaso S, Giacomuzzi M. Prevalence of anti-legionella antibodies among Italian hospital workers. J Hosp Infect 2008; 69: 148-155.
37.
Murdoch DR, Podmore RG, Anderson TP, Barratt K, Maze MJ, French KE, Young SA, Chambers ST, Werno AM. Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires’ disease: a pre-post comparison study. Clin Infect Dis 2013; 57: 1275-1281.
39.
Heuser W, Tirmizi S, Frieri M, Boutin A, Kumar K, Politi V. Legionella pneumophila: diagnosis and management for the critically ill and septic patient: a review of the literature. Clin Pulm Med 2017; 24: 6-12.
40.
Waterer GW. Diagnosing viral and atypical pathogens in the setting of community-acquired pneumonia. Clin Chest Med 2017; 38: 21-28.
41.
Cristovam E, Almeida D, Caldeira D, Ferreira JJ, Marques T. Accuracy of diagnostic tests for Legionnaires’ disease: a systematic review. J Med Microbiol 2017; 66: 485-489.
42.
Chahin A, Opal SM. Severe pneumonia caused by Legionella pneumophila: differential diagnosis and therapeutic considerations. Infect Dis Clin 2017; 31: 111-121.
43.
Jasper AS, Musuuza JS, Tischendorf JS, Stevens VW, Gamage SD, Osman F, Safdar N. Are fluoroquinolones or macrolides better for treating Legionella pneumonia? A systematic review and meta-analysis. Clin Infect Dis 2021; 72: 1979-1989.
44.
Karer M, Haider T, Kussmann M, Obermüller M, Tiehen C, Burgmann H, Lagler H, Traby L. Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital. Int J Antimicrob Agents 2022; 59: 106481.
45.
Saikku P. The epidemiology and significance of Chlamydia pneumoniae. J Infect 1992; 25: 27-34.
46.
Yu Y, Fei A. Atypical pathogen infection in community-acquired pneumonia. Biosci Trends 2016; 10: 7-13.
47.
Sharma L, Losier A, Tolbert T, Dela Cruz CS, Marion CR. Atypical pneumonia: updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clin Chest Med 2017; 38: 45-58.
48.
Perrone T, Quaglia F. Lung US features of severe interstitial pneumonia: case report and review of the literature. J Ultrasound 2017; 20: 247-249.
49.
Miyashita N. Atypical pneumonia: pathophysiology, diagnosis, and treatment. Respir Investig 2022; 60: 56-67.
50.
Smith-Norowitz TA, Shidid S, Norowitz YM, Kohlhoff S. Chlamydia pneumoniae-induced IFN-gamma responses in peripheral blood mononuclear cells increase numbers of CD4+ but not CD8+ T effector memory cells. J Blood Med 2021; 12: 385-394.
51.
She RC, Thurber A, Hymas WC, Stevenson J, Langer J, Litwin CM, Petti CA. Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections. J Clin Microbiol 2010; 48: 3380-3382.
52.
Villegas E, Sorlózano A, Gutiérrez J. Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives. J Med Microbiol 2010; 59: 1267-1274.
53.
Benitez AJ, Thurman KA, Diaz MH, Conklin L, Ken- dig NE, Winchell JM. Comparison of real-time PCR and a microimmunofluorescence serological assay for detection of chlamydophila pneumoniae infection in an outbreak investigation. J Clin Microbiol 2012; 50: 151-153.
54.
Rahman KS, Kaltenboeck B. Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of conventional Chlamydia pneumoniae serology. Sci Rep 2019; 9: 15078.
55.
Radouani F, El Yazouli L, Elyazghi Z, Hejaji H, Alami AA, Elmdaghri N. Chlamydia pneumoniae sero-prevalence in Moroccan patients with cardiovascular diseases. Infect Dis Health 2019; 24: 67-74.
56.
Hagemann JB, Simnacher U, Marschall MT, Maile J, Soutschek E, Wellinghausen N, Essig A. Analysis of humoral immune responses to recombinant Chlamydia pneumoniae antigens. Int J Infect Dis 2020; 91: 232-239.
57.
Miyashita N, Akaike H, Teranishi H, Kawai Y, Ouchi K, Kato T, Hayashi T, Okimoto N. Evaluation of serological tests for diagnosis of Chlamydophila pneumoniae pneumonia in patients with nursing and healthcare-associated pneumonia. J Infect Chemother 2013; 19: 249-255.
58.
Strålin K, Fredlund H, Olcén P. Labsystems enzyme immunoassay for Chlamydia pneumoniae also detects Chlamydia psittaci infections. J Clin Microbiol 2001; 39: 3425-3426.
59.
Kohlhoff SA, Hammerschlag MR. Treatment of Chlamydial infections: 2014 update. Expert Opin Pharmacother 2015; 16: 205-212.
61.
Murphy CN, Fowler R, Balada-Llasat JM, Carroll A, Stone H, Akerele O, Buchan B, Windham S, Hopp A, Ronen S, Relich RF, Buckner R, Warren DA, Humphries R, Cam- peau S, Huse H, Chandrasekaran S, Leber A, Everhart K, Harrington A, Kwong C, Bonwit A, Bard JD, Naccache S, Zimmerman C, Jones B, Rindlisbacher C, Buccambuso M, Clark A, Rogatcheva M, Graue C, Bourzac KM. Multicenter evaluation of the BioFire FilmArray pneumonia/Pneumonia Plus Panel for detection and quantification of agents of lower respiratory tract infection. J Clin Microbiol 2020; 58: e00128-20.
62.
Enne VI, Aydin A, Baldan R, Owen DR, Richardson H, Ricciardi F, Russell C, Nomamiukor-Ikeji BO, Swart AM, High J, Colles A, Barber J, Gant V, Livermore DM, O’Grady J; INHALE WP1 Study Group. Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. Thorax 2022; 77: 1220-1228.
63.
Jamal W, Albert MJ, Rotimi VO. Real-time comparative evaluation of bioMerieux VITEK MS versus Bruker Microflex MS, two matrix-assisted laser desorption-ionization time-of-flight mass spectrometry systems, for identification of clinically significant bacteria. BMC Microbiol 2014; 14: 289.
64.
Gadsby NJ, McHugh MP, Forbes C, MacKenzie L, Hamilton SKD, Griffith DM, Templeton KE. Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting. Eur J Clin Microbiol Infect Dis 2019; 38: 1171-1178.
65.
Wagner K, Springer B, Imkamp F, Opota O, Greub G, Keller PM. Detection of respiratory bacterial pathogens causing atypical pneumonia by multiplex Lightmix® RT-PCR. Int J Med Microbiol 2018; 308: 317-323.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
